Ingevity Corporation
$53.75-$2.21 (-3.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $2.3B
- P/E
- -13.8x
- EV / EBITDA
- 83.6x
- Revenue
- $1.2B
- Net margin
- -14.3%
- ROCE
- 20.0%
Price chart
Technical chartScreen technicals →+13.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -23.9%
- 3M
- -22.4%
- 6M
- -18.7%
- 1Y
- +13.2%
- 5Y
- -31.8%
52-week range
Day change -$2.21 (-3.9%) from $56 to $54 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in NGVT, bought on each weekday since 2021.
News & filings
What Ingevity filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 167 million US dollars in fiscal 2025.
Strengths (1)
- Operating margin of 22.4% against a peer median of 7.5%.
- Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Read moreShow less
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats. This segment also produces other activated carbon products for food, water, beverage, and chemical purification applications. The Performance Chemicals segment consists of road technologies and industrial specialties. This segment's products are used in pavement construction, pavement preservation, pavement reconstruction and recycling, road markings, agrochemical dispersants, lubricants, certain adhesives, rubber, and other industrial uses. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices. It serves automotive parts manufacturers through sales representatives, third-party sales representatives, and distributors. The company was formerly known as WestRock Company, Specialty Chemicals Business and changed its name to Ingevity Corporation in September 2015. Ingevity Corporation was founded in 1964 and is headquartered in North Charleston, South Carolina.
- Sector
- Basic Materials
- Shares outstanding
- 35.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.3B
- P/E
- -13.8x
- P/B
- 77.4x
- EV / EBITDA
- 83.6x
- EV / Sales
- 3.0x
- P/S
- 2.0x
- 52-week high
- $77.87
- 52-week low
- $47.48
Profitability
- Operating margin
- 22.4%
- Net margin
- -14.3%
- EBITDA margin
- 3.5%
- ROE
- -562.6%
- ROCE
- 20.0%
- ROA
- -10.1%
- Asset turnover
- 0.71
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.2B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -2.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -11.2%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -61.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $273.5M
Solvency
- Current ratio
- 1.33
- Debt / Equity
- 41.84
- Debt / Assets
- 0.75
- CFO / Net profit
- -1.98
- Cash / Market cap
- 3.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $1.2B |
| Cost of revenue | $706.1M |
| Gross profit | $461.5M |
| Operating expenses | $199.6M |
| Research and development | $28.4M |
| Selling, general and administrative | $171.2M |
| Operating income | $261.9M |
| Interest and other | -$404.0M |
| Pretax income | -$142.1M |
| Tax and other | $25.0M |
| Net income | -$167.1M |
Revenue and net profit
Revenue fell 2.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $1.7B | $211.6M |
| FY2023 | $1.2B | -$5.4M |
| FY2024 | $1.2B | -$430.3M |
| FY2025 | $1.2B | -$167.1M |
Cash flows
FY2025: $331.2M from operations, $273.5M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $313.4M | $170.9M |
| FY2023 | $205.1M | $95.3M |
| FY2024 | $128.6M | $51.0M |
| FY2025 | $331.2M | $273.5M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.2B-2.7%1Y
- EBITDA
- $41.4M-35.7%1Y
- Net profit
- -$167.1M
- Cash from operations
- $331.2M+157.5%1Y
- Free cash flow
- $273.5M+436.3%1Y
- Revenue CAGR, 3Y
- -11.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.2B | $41.4M | -$167.1M | $273.5M | -562.6% | -2.7% | -61.2% |
Monthly returns
Month-by-month returns of NGVT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.7B |
| Current assets | $454.2M |
| Non-current assets | $1.2B |
| Liabilities | $1.6B |
| Current liabilities | $341.3M |
| Non-current liabilities | $1.3B |
| Equity | $29.7M |
| Paid-in capital | $195.7M |
| Retained earnings | $404.9M |
| Treasury stock | $571.8M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Basic Materials companies placed by value, growth and quality; NGVT highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Ingevity CorporationNGVTthis company | $2.3B | -13.8x | 77.4x | -562.6% | 83.6x |
| The Chemours CompanyCC | $3.3B | — | 13.0x | -154.4% | 21.0x |
| Hawkins, Inc.HWKN | $3.2B | 39.0x | 6.0x | 15.3% | 19.6x |
| Kaiser Aluminum CorporationKALU | $3.1B | 27.1x | 3.7x | 13.6% | 12.8x |
| Alpha Metallurgical Resources, Inc.AMR | $2.7B | -44.4x | 1.8x | -4.0% | 25.0x |
| WD-40 CompanyWDFC | $2.7B | 30.1x | 10.2x | 33.8% | 24.5x |
| Quaker Chemical CorporationKWR | $2.4B | -982.0x | 1.8x | -0.2% | 21.9x |
| Boise Cascade CompanyBCC | $2.4B | 18.1x | 1.2x | 6.4% | 6.7x |
| Minerals Technologies Inc.MTX | $2.4B | -129.3x | 1.4x | -1.1% | 22.9x |
| Peer median | — | 18.1x | 2.7x | 3.1% | 21.5x |
Year-to-date ROI
NGVT since 1 January, against earlier years.
Historical volatility
NGVT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 20.4% |
| FY2023 | 21.2% |
| FY2024 | 23.5% |
| FY2025 | 22.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.2B |
| Cost of revenueCost Of Revenue | $706.1M |
| Gross profitGross Profit | $461.5M |
| Operating expensesOperating Expense | $199.6M |
| Research and developmentResearch And Development | $28.4M |
| Selling, general and administrativeSelling General And Administration | $171.2M |
| Total expensesTotal Expenses | $905.7M |
| Operating incomeOperating Income | $261.9M |
| Interest and other | |
| Pretax incomePretax Income | -$142.1M |
| TaxTax Provision | $8.2M |
| Net incomeNet Income | -$167.1M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.7B |
| Current assetsCurrent Assets | $454.2M |
| Non-current assetsTotal Non Current Assets | $1.2B |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.6B |
| Current liabilitiesCurrent Liabilities | $341.3M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.3B |
| EquityTotal Equity Gross Minority Interest | $29.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $331.2M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $331.2M |
| Net income, continuing operationsNet Income From Continuing Operations | -$167.1M |
| Depreciation and amortisationDepreciation And Amortization | $106.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $106.4M |
| Stock-based compensationStock Based Compensation | $18.3M |
| Deferred taxDeferred Tax | -$4.7M |
| Deferred income taxDeferred Income Tax | -$4.7M |
| Operating gains and lossesOperating Gains Losses | $30.6M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $26.2M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Asset impairmentAsset Impairment Charge | $293.1M |
| Provision and write off of assetsProvisionand Write Offof Assets | — |
| Pension and employee benefit expensePension And Employee Benefit Expense | $1.2M |
| Change in working capitalChange In Working Capital | $22.7M |
| Other non-cash itemsOther Non Cash Items | $31.9M |
| Investing cash flowInvesting Cash Flow | -$57.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$57.5M |
| Capital expenditureCapital Expenditure | -$57.7M |
| Capital expenditure (reported)Capital Expenditure Reported | -$57.7M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | -$16.4M |
| Sale of investmentsSale Of Investment | $13.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$3.4M |
| Other investing changesNet Other Investing Changes | $3.6M |
| Financing cash flowFinancing Cash Flow | -$252.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$252.2M |
| Debt issuedIssuance Of Debt | $291.3M |
| Debt repaidRepayment Of Debt | -$483.6M |
| Net debt issuedNet Issuance Payments Of Debt | -$193.6M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $291.3M |
| Long-term debt repaidLong Term Debt Payments | -$483.6M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$193.6M |
| Net common stock issuedNet Common Stock Issuance | -$56.3M |
| Common stock repurchasedCommon Stock Payments | -$56.3M |
| Share buybacksRepurchase Of Capital Stock | -$56.3M |
| Stock options exercisedProceeds From Stock Option Exercised | $1.4M |
| Other financing chargesNet Other Financing Charges | -$3.7M |
| Change in cashChanges In Cash | $21.5M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 450.0% |
| Cash at the start of the yearBeginning Cash Position | $86.6M |
| Cash at the end of the yearEnd Cash Position | $112.6M |
| Free cash flowFree Cash Flow | $273.5M |
| Supplemental |
Learn while you research
Academy chapters picked for Ingevity Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Leverage RatiosDebt/Equity of 41.84 is elevated, understand what that means for solvency.6 min read
- 03 Business Cycles & StocksThese cyclical sectors win and lose in different macro phases.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read